AnaptysBio
ANAB
133 hedge funds and large institutions have $658M invested in AnaptysBio in 2024 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 40 increasing their positions, 41 reducing their positions, and 12 closing their positions.
117% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 12
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
12% more funds holding
Funds holding: 119 → 133 (+14)
4% more call options, than puts
Call options by funds: $1.47M | Put options by funds: $1.41M
0% less capital invested
Capital invested by funds: $659M → $658M (-$1.28M)
2% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 41
6.61% less ownership
Funds ownership: 115.81% → 109.2% (-6.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$18.1M |
| 2 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$16.3M |
| 3 |
Millennium Management
New York
|
+$5.69M |
| 4 |
SC
Stempoint Capital
New York
|
+$5.32M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$35.7M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
-$16.2M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$14.7M |
| 4 |
Morgan Stanley
New York
|
-$13.4M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$7.6M |
ANAB Hedge Fund Activity: Q1 2024 in Review
133 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2024, worth a combined $658M — down 0.19% from $659M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ANAB positions and 12 closed out — a net gain of 14 holders — while 40 added to existing stakes and 41 trimmed.
The largest buyer was State Street, adding an estimated $18.1M. The largest seller was Deep Track Capital, cutting an estimated $35.7M.
- 133 institutional investors held AnaptysBio (ANAB) as of Q1 2024, up from 119 in Q4 2023.
- Funds reported $658M of AnaptysBio stock for Q1 2024, down 0.19% quarter-over-quarter.
- 26 funds opened new AnaptysBio positions in Q1 2024 and 12 closed out, a net change of +14 holders.
- The largest AnaptysBio buyer in Q1 2024 was State Street, an estimated $18.1M added.
- The largest AnaptysBio seller in Q1 2024 was Deep Track Capital, an estimated $35.7M sold.
Based on aggregated 13F filings for Q1 2024.